DSM NV

Délocalisation: Will restructure its money-losing anti-infectives business, closing capacity in Europe and increasing output in Asia. 13% of the business's total will go. Weak markets, the decline of the dollar, and strong growth in Asia are cited as main reasons for the restructuring. A plant at Delft and a plant at Geleen, the Netherlands, will close in 2005. A joint venture with Glaxo SmithKline at Irvine, UK is to end in 2005. DSM is to expand and upgrade production at its anti-infectives plant at Toansa, India, and at its joint venture's at Harbin, Zhang Jiakou, and Zibo, China. The restructuring should mean annualized cost savings of tens of millions of euros within two years. traduire :

Restructuration interne: Pays-Bas

18375